All Stories

  1. Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1 ‐mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID‐1...

    Article • British Journal of Haematology, July 2020, Wiley

    Robert Baker

  2. Successful remission induction therapy with gilteritinib in a patient with de novo FLT3 ‐mutated acute myeloid leukaemia and severe COVID‐19

    Article • British Journal of Haematology, July 2020, Wiley

    Robert Baker